Search Results - hodgkin+lymphoma

2 Results

Sort By:

Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs)

Abstract: Immortalization of plasma cells leads to plasma cell malignancy diseases such as multiple myeloma (MM). B-cell maturation antigen (BCMA) is a protein that is preferentially expressed by malignant and normal B cells and plasma cells, butnot on other cells in the body. This limited expression profile suggests that BCMA is a promising target...

Published: 8/14/2024 | Inventor(s): James Kochenderfer, Norris Lam, Benjamin Buelow

Keywords(s): act, adoptive cell therapy, B-cell Malignancies, B-cell Maturation Antigen, BCMA, BIOLOGIC, CANCER, CAR, chimeric antigen receptor, Hodgkin Lymphoma, Hodgkin’s Lymphoma, Kochenderfer, Mm, MULTIPLE MYELOMA, Non-Hodgkin Lymphoma, Non-Hodgkin’s Lymphoma, Plasma Cell Malignancies

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Efficacious Fluorinated Cytidine Analog Cancer Therapeutic With Low Toxicity In Animal Studies

Abstract: Cytidine analogs remain an area of active drug discovery and development, with five FDA approved drugs for the treatment of acute myeloid leukemia (AML). Two of these drugs, azacitidine (Vidaza®) and decitabine (Dacogen®), which were approved for myelodysplastic syndromes in 2004 and 2006, respectively, inhibit the DNA maintenance...

Published: 4/8/2024 | Inventor(s): Joel Morris, Omar Lopez, Donn Wishka

Keywords(s): colon carcinoma, cytidine analogs, Hodgkin Lymphoma, Morris

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology